STOCK TITAN

Alector to Participate in Upcoming Healthcare Conferences

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Alector (Nasdaq: ALEC), a clinical-stage biotechnology company focused on immuno-neurology, has announced its participation in three upcoming healthcare conferences in September 2024. The company will be present at:

  • Morgan Stanley 22nd Annual Global Healthcare Conference on September 5
  • H.C. Wainwright 26th Annual Global Investment Conference on September 9
  • 2024 Cantor Global Healthcare Conference on September 17

All events will take place in New York City, featuring fireside chats with Alector's management. Webcasts of these presentations will be available on Alector's investor relations website, with replays accessible for 90 days after each event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction

+0.19%
1 alert
+0.19% News Effect

On the day this news was published, ALEC gained 0.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

  • Morgan Stanley 22nd Annual Global Healthcare Conference (New York, New York)
    • Thursday, September 5, 2024, at 7:45 a.m. ET, fireside chat
  • H.C. Wainwright 26th Annual Global Investment Conference (New York, New York)
    • Monday, September 9, 2024, at 10:00 a.m. ET, fireside chat
  • 2024 Cantor Global Healthcare Conference (New York, New York)
    • Tuesday, September 17, 2024, at 9:45 a.m. ET, fireside chat

A webcast of each presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About Alector
Alector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California. For additional information, please visit www.alector.com.

Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com

1AB (media)
Dan Budwick
973-271-6085
dan@1abmedia.com

Argot Partners (investors)
Laura Perry
212.600.1902
alector@argotpartners.com


FAQ

What investor conferences will Alector (ALEC) participate in during September 2024?

Alector will participate in three conferences: Morgan Stanley Global Healthcare Conference on September 5, H.C. Wainwright Global Investment Conference on September 9, and Cantor Global Healthcare Conference on September 17, 2024.

Where can investors access the webcasts of Alector's (ALEC) conference presentations?

Webcasts of Alector's presentations will be available on the 'Events & Presentations' page within the Investors section of the Alector website at http://investors.alector.com.

How long will the replays of Alector's (ALEC) conference presentations be available?

Replays of the webcasts will be available on the Alector website for 90 days following each presentation date.

What type of company is Alector (ALEC)?

Alector is a clinical-stage biotechnology company pioneering immuno-neurology.
Alector

NASDAQ:ALEC

ALEC Rankings

ALEC Latest News

ALEC Latest SEC Filings

ALEC Stock Data

208.48M
98.25M
10.37%
77.1%
5.36%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO